Superiority of Mature Differentiated Cultured Human Corneal Endothelial Cell Injection Therapy for Corneal Endothelial Failure
Superiority of Mature Differentiated Cultured Human Corneal Endothelial Cell Injection Therapy for Corneal Endothelial Failure
复制标题
成熟分化培养人角膜内皮细胞注射治疗角膜内皮衰竭的优越性
DOI：
10.1016/j.ajo.2021.11.012
复制
发表时间：
2022
影响因子：
4.2
通讯作者：
KINOSHITA SHIGERU
中科院分区：
文献类型：
--
作者：
UENO MORIO;TODA MUNETOYO;NUMA KOHSAKU;TANAKA HIROSHI;IMAI KOJIRO;BUSH JOHN;TERAMUKAI SATOSHI;OKUMURA NAOKI;KOIZUMI NORIKO;YAMAMOTO AKIHISA;TANAKA MOTOMU;SOTOZONO CHIE;HAMURO JUNJI;KINOSHITA SHIGERU
目的：研究培养的人角膜内皮细胞（hCEC）注射疗法与成熟分化（成熟）细胞亚群（SP）治疗角膜内皮衰竭（CEF）的安全性和有效性。方法：本研究涉及18只接受培养的hCEC注射疗法的CEF眼睛，分为2组：（1）11只眼睛给予相对较低比例（0.1 - 76.3%）的成熟细胞SP（组1 [Gr1]），（2）7只眼睛给予相对较高比例（> 90%）的成熟细胞SP（组2 [Gr2]）。术后1周~3年记录角膜内皮细胞（CEC）密度（CECD）、中央角膜厚度（CCT）和最佳矫正视力（BCVA），计算CEC参数的"弹簧常数"。术后3年，11只Gr1眼中10只眼和11只Gr2眼的角膜恢复良好，BCVA提高，Gr2眼的中位CECD降低，（3083个细胞/mm 2;范围，2182 - 4417个细胞/mm 2）高于Gr1（1349个细胞/mm 2;范围，746 - 2104个细胞/mm 2）（P <.001），并且弹簧常数证实了成熟培养的hCEC的优越性。从术后24周至3年，CECD下降的中位百分比在Gr2中为3.2%，在Gr1中为23.6%（P <0.005）。CCT在Gr2中迅速且恒定地恢复，而在Gr1中则不同。没有不良事件observed.CONCLUSION我们的研究结果表明，成熟细胞SP的hCEC注射治疗提供快速恢复CCT，更好的CECD，和低CECD磨损超过3年术后。
PURPOSETo investigate the safety and efficacy of cultured human corneal endothelial cell (hCEC) injection therapy with mature differentiated (mature) cell subpopulations (SPs) for corneal endothelial failure (CEF).DESIGNComparative, interventional case series.METHODSThis study involved 18 eyes with CEF that underwent cultured hCEC injection therapy, categorized into 2 groups: (1) 11 eyes administered a relatively lower proportion (0.1 to 76.3%) of mature cell SPs (group 1 [Gr1]), and (2) 7 eyes administered a relatively higher proportion (>90%) of mature cell SPs (group 2 [Gr2]). From 1 week to 3 years postoperation, corneal endothelial cell (CEC) density (CECD), central corneal thickness (CCT), and best-corrected visual acuity (BCVA) were recorded, and the CEC parameter's “spring constant” was calculated. The proportion of mature SPs was evaluated by fluorescence-activated cell sorting analysis based on cell-surface markers.RESULTSAt 3 years postoperation, corneal restoration with improved BCVA was attained in 10 of the 11 Gr1 eyes and all Gr2 eyes, the median CECD in Gr2 (3083 cells/mm2; range, 2182-4417 cells/mm2) was higher than that in Gr1 (1349 cells/mm2; range, 746-2104 cells/mm2) (P< .001), and the spring constant verified the superiority of the mature cultured hCECs. From 24 weeks through 3 years postoperation, the median percentage of CECD decrease was 3.2% in Gr2 and 23.6% in Gr1 (P< .005). CCT recovery was prompt and constant in Gr2, while diverse in Gr1. No adverse events were observed.CONCLUSIONOur findings showed that mature cell SPs for hCEC injection therapy provide rapid recovery of CCT, better CECD, and low CECD attrition over 3 years postsurgery.